Business Wire

Chartbeat Announces New Funding to Fuel Growth

25.7.2018 16:00:00 EEST | Business Wire | Press release

Share

Chartbeat, the content intelligence platform for the world’s leading publishers, today announced that the company has closed a $7 million funding round, led by North Atlantic Capital. The capital will enable Chartbeat to accelerate its leadership position in real-time analytics across desktop, social, and mobile platforms.

2018 has seen unprecedented traffic shifts, and Chartbeat provides media organizations with instant insights about content engagement and reader traffic — whether directly on publisher websites or from platforms such as Facebook and Google. Empowered with data, media organizations can better understand, measure, and build business value from the attention earned by their content.

“Our solid revenue growth and product expansion efforts have put us on a bright path forward,” said John Saroff, Chartbeat’s CEO. “We’re thrilled to have North Atlantic Capital behind us as we continue to scale.” Saroff added, “Chartbeat’s analytics enable publishers to connect with valuable readers and grow a sustainable business. We’ll continue to build out our core business while expanding into new areas within mobile and multivariate testing.”

Today's investment follows a period of rapid growth for Chartbeat, whose customer base now includes the top global media, sports and entertainment brands in over 65 countries. Clients include The New York Times, The Washington Post, The Atlantic and ESPN in the US; the Economist, The Telegraph and The Mirror in the UK; Le Figaro and Le Monde in France, Unidad in Spain; Clarin in Argentina; and The South China Morning Post in Hong Kong, to name a few.

"This is a very strong team – impressively talented and dedicated to solving a real need for publishers," said Mark Morrissette, Managing Director at North Atlantic Capital. “With such passionate customers, we see a lot of opportunity for Chartbeat to expand both within its base and into adjacent markets. This is a great fit for us.”

This late stage funding brings the total amount of money Chartbeat has raised since 2009 to $38 million. North Atlantic will immediately join Chartbeat’s Board of Directors as a board observer, along with investors and board members DFJ, Index Ventures and Betaworks, and board observer Harmony Partners.

About Chartbeat

Chartbeat, the content intelligence platform for publishers, empowers media companies to build loyal audiences with real-time and historical editorial analytics across desktop, social, and mobile platforms. Chartbeat helps digital publishing organizations understand what, within their content, is keeping people engaged. Partnering with thousands of customers across 65 countries, Chartbeat’s real-time and historical dashboards, in-depth headline testing and in-page optimization tools, robust reporting, and APIs help the world’s leading media organizations understand, measure, and build business value from the attention earned by their content.

About North Atlantic Capital

North Atlantic Capital provides growth capital to innovative technology companies across the United States. Founded in 1986 and based in Portland, Maine, the firm is currently investing its fifth fund, which is capitalized at more than $120 million. North Atlantic targets high-growth, later-stage technology businesses with annual revenues of more than $10 million. North Atlantic has a 30-year history of supporting rapidly growing technology companies with both equity and long-term subordinated investments. https://www.northatlanticcapital.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Chartbeat
Terri Walter, 646-932-7654
or
Lauryn Bennett, 781-635-6141
press@chartbeat.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye